Ryerson Holding Corporation will announce its financial results for the third quarter of 2026 after market close on October 28. The company will hold a conference call on October 29 at 10 a.m. ET to discuss the results. Ryerson is a major processor and distributor of industrial metals operating in North America and China, with a long history dating back to 1842. Investors can access the live call and replay on Ryerson's investor relations website.
Ryerson Holding Corporation's upcoming earnings call is the context for this market snapshot. For readers following Basic Materials, here is Pluang's market data as of Oct 02, 2026 02:41 WIB: Of 38 priced US Basic Materials stocks, 9 rose and 28 fell. Notable movers include LAC at USD 2.56 with a -2.47% change and a typical hold time of 26 days, SLI at USD 1.78 down 2.46%, and SCCO at USD 198.11 down 2.24% with a 60-day hold time and 98% buy order activity on Pluang.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
